This study is currently not recruiting participants.

A Phase 2b double-blind randomized placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)

Study on Investigational Medications for Dementia with Lewy Bodies

Not Recruiting
50 years - 85 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to investigate how well RVT-101 works to improve cognitive and overall function as well as to investigate the safety of RVT-101.

Detailed description of study

The purpose of this study is to test PVT-101 to evaluate whether it can help cognition and overall function in subjects with dementia with Lewy bodies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: dementia
  • Age: 50 years - 85 years
  • Gender: All

This study investigates how well an investigational medication works to improve thinking skills and overall function in people with dementia with Lewy bodies. Dementia with Lewy bodies is a brain disorder that affects memory, thinking, and movement.

Participants will receive either the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. This helps researchers compare the effects of the medication with no treatment.

  • Who can participate: Participants aged 50 to 85 years with a diagnosis of dementia with Lewy bodies may be eligible. Key criteria include stable medical conditions and no significant psychiatric disorders.
  • Study details: Participants will be assigned to receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1603122491

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team